Left ventricular hypertrophy (LVH) has been recognized as an important cardiovascular risk factor. Hypertensive disease is the most frequent background of LVH and it is generally felt that anti-hypertensive treatment should not only lower blood pressure but also cause regression of LVH. In the present survey the patho-physiology of LVH, its measurements and animal models used to study LVH are briefly discussed. Subsequently, the effects of various drugs in animal models and in human hypertensives are reviewed. It has been shown repeatedly that various types of antihypertensive drugs show differential activities on the prevention or regression of LVH. It is not only the lowering of blood pressure which determines the anti-LVH activity, but also the interaction of drugs with neuro-endocrine mechanisms such as the renin-angiotensin-aldosterone system and the sympathetic nervous system.
Introductory remarks 2. Pathological left ventricular hypertrophy (LVH)
LVH has already been recognized as a strong, virtually Left ventricular hypertrophy (LVH) was recognized as independent risk factor in the well-known Framingham early as in the Framingham [1] study as an important Study [1] . Various noxious sequelae of cardiovascular cardiovascular risk factor. Since then much attention has diseases and conditions such as coronary heart disease, been paid to LVH associated with hypertensive disease. stroke, congestive heart failure and sudden death are Early animal experiments in the 1970s have shown that known to be aggravated by LVH [3] . LVH can be prevented or brought to regression by a LVH is the result of adaptation of the heart to chronic variety of antihypertensive drugs. The paper by Pegram et pressure or volume overload, and more recently neuroal., published in Cardiovascular Research in 1982 [2] has endocrine activation processes have been recognized to been quoted many times as representative of this type of play an important role as well [3, 4] . research. Since then the subject has been studied intensive-
In the general population hypertension is the most ly in animal models and subsequently in human patients, common cause of LVH. The geometrical characteristics of owing to the introduction of non-invasive techniques LVH may differ, also with respect to the increased risk of which allow the measurement of LVH.
the aforementioned sequelae of cardiovascular diseases. The drug treatment of hypertension has been much Concentric hypertrophy is known to be associated with the refined since then, and it is generally felt that antihyperhighest risk and LVH with normal geometry with the tensive treatment should also be accompanied by the lowest risk, whereas LVH with eccentric hypertrophy is regression of LVH. associated with intermediate risk [4, 5] . The present survey will be dealing both with results
The question whether LVH should be considered as obtained since the 1980s in animal models and in human pathologic cannot be judged on morphological criteria hypertensives.
only. For instance, the increased LV wall thickness in highly trained athletes is not necessarily pathologic and additional criteria (ECG in particular) are required to distinguish between an athlete's heart and a pathologically enlarged heart [6] . The hypertrophic heart as in hyper-trophic cardiomyopathy (HCM) is clearly a pathological oedema, increased pulmonary artery wall thickness, and condition with a strong genetic background, but not renal hypertrophy [18] . associated with a coexisting cardiac or systemic disease Finally, myocardial infarction evoked in rats by corthat could provoke LVH [7] . onary arterial ligation leads to concentric hypertrophy of In the present survey the discussion will be limited to the septum and the myocardial tissues of the heart cavities pathologic LVH associated with hypertensive disease.
with a large increase in the thickness of the ventricular At the cellular / molecular level various factors and septum [19] . After 1-2 months following coronary ligation mechanisms have been implied in the genesis and maintethe aforementioned characteristics of hypertrophy are fully nance of LVH. Widely recognized growth factors are for developed, but blood pressure has been lowered when instance the catecholamines (noradrenaline, adrenaline), compared with control animals. angiotensin II, insulin, and the human growth hormone [8] .
The evaluation and quantification of cardiac hypertrophy Much attention has been paid in addition to receptor and remodelling in experimental animals is clearly easier changes (a-and b-adrenoceptors; angiotensin II (AT)-and more precise than in human patients, where only receptors, etc.) associated with LVH.
indirect techniques can be applied. In animal models the Taken together, pathological LVH is generally recoghearts can be removed, weighed, and then subjected to a nized as an important process, which is associated with variety of morphological and biochemical analyses, as significant structural, haemodynamic, and cellular changes.
already performed in the original study by Pegram et al. Since LVH is also recognized to indicate an unfavourable [2] . prognosis, it is not surprising that numerous therapeutic approaches have been pursued with the aim to induce 2.2. Receptor changes associated with LVH regression of LVH and, hence, a reduction of cardiovascular risk.
Numerous data have been gathered with respect to possible changes in the characteristics of cardiac receptors, associated with pathological LVH. Such receptor changes 2.1. Animal models may be of potential interest concerning the influence of drug treatment aiming at the regression of LVH. LVH has been studied in animal models from the 1970s
Experimental data concerning changes in cardiac reonwards, in particular by R. Tarazi and E. Frohlich and ceptors are not clearly consistent, and rather different in their co-workers [2, 9, 10] . Most hypertensive animals as the various experimental models which were investigated. used in various models of hypertension develop LVH, With respect to cardiac b-adrenoceptors no major changes more or less parallel with the rise in blood pressure.
were found in the inotropic responses to various types of Examples of such models are various types of hypertensive b-adrenoceptor agonists in moderately hypertrophied rats (in particular the spontaneously hypertensive rat5 hearts of young SHR, but a gradual blunting of the SHR) and rats, guinea pigs or ferrets subjected to aortic or responsiveness occurred in hearts with a much more severe pulmonary artery banding [11] [12] [13] . The original inves-LVH taken from animals subjected to aortic banding and tigation by Pegram et al. [2] also used SHR. LVH can also from older SHR [20, 21] . This blunting of the responsivebe evoked by increasing cardiac afterload by means of ness of the b-adrenoceptor pathway appears to be rather infusions of noradrenaline or other vasoconstrictors, such secondary to post receptor events than the result of as angiotensin II, or by the long term administration of changes in the characteristics of the surface receptors. b -adrenoceptor agonists such as dobutamine [14, 15] . 1 In hypertrophied hearts from SHR and from rats subjectThe induction of LVH in animal models is not necessaried to aortic banding an impaired responsiveness to a -1 ly always accompanied by hypertension. Rapid pacing of receptor stimulation was also found, whereas there were no dog hearts for several weeks or goat atria for 24 h induces detectable changes in the characteristics of the surface LV hypertrophy and atrial remodelling, respectively, which receptors [22] . Only in animals with severe LVH the is not accompanied by hypertension [16] . A well-known cardiac a -receptor density was reduced, indicating that 1 model of cardiomegaly without associated hyper-tension is intracellular alterations will precede the changes at the offered by the cardiomyopathic Syrian hamster. The surface receptor level. For review see [23] . genetically determined cardiomyopathy in these animals is Metabolic changes have also been observed in associaassociated with congestive heart failure but not with high tion with LVH. For review see [24] . blood pressure [17] .
For the sake of completeness we mention a rat model of right ventricular hypertrophy (RVH), accompanied by severe right heart failure. This condition of RVH was 3. LVH in patients: how to measure it obtained by means of a single subcutaneous injection of monocrotaline, which after 4-6 weeks led to marked right Over the years a few non-invasive methods have been ventricular and right atrial hypertrophy, pulmonary introduced which are now accepted to offer valid criteria to establish and quantify LVH in patients. We briefly mention 3. primary hypertension in humans has a much longer these methods here.
time scale than in animal models. Electrocardiography is not suitable for an accurate screening of LVH because it is much less sensitive than Without attempting completeness we will present a few more modern methods such as ECHO-cardiography. Howrelevant examples concerning the influence of various ever, once electrocardiographic LVH has been detected it drugs on LVH in animal models. has a high predictive value for morbidity and mortality. For this reason the ECG should not be discarded as a 4.1. Centrally acting antihypertensives widely available and cheap technique for the clinical diagnosis of LVH. The same holds for chest X-ray pictures These agents were studied extensively with respect to [25] .
the regression / prevention of LVH in animal models, in ECHO-cardiography has become the most widely used particular SHR, by the Tarazi Group as early as the 1970s technique to diagnose and quantify LVH in patients [5, 25] . [9, 10] . M-mode echocardiography is well suited for estimating
Clonidine and a-methyl-DOPA (via its active metabolite differences in left ventricular mass indices (LVMI) bea-methyl-noradrenaline) cause peripheral sympathoinhibitween groups of subjects, but it underestimates the prevaltion which is triggered by a central nervous mechanism ence of LVH [5, 25] . located in the brain stem. a-Methylnoradrenaline is a Nuclear magnetic resonance imaging provides 'global' selective stimulant of central a -adrenoceptors, whereas 2 and more accurate information about left ventricular clonidine stimulates both imidazoline (I )-receptors and 1 structure, but this technique is much more expensive than a -adrenoceptors [28] .
2 echocardiography [26, 27] . In SHR both sympathoinhibitory agents significantly reduced the elevated blood pressure. However, a-methyl-DOPA prevented the development of LVH, whereas
The influence of drugs on LVH in animal models
clonidine did not, as already discussed in the original publication by Pegram et al. [2] . In a later stage moxIn general terms the vast majority of antihypertensive onidine and rilmenidine were developed as centrally acting drugs will cause regression of LVH in a variety of animal anti-hypertensives. Both compounds trigger peripheral models, and there exists a large body of literature on this sympathoinhibition via the stimulation of imidazoline (I )-1 subject. Globally spoken drugs that lower blood pressure receptors in the brain, whereas they have much less affinity without causing a marked stimulation of either the sympafor the a -adrenoceptor. Both I -receptor stimulants are 2 1 thetic nervous system or the renin-angiotensin-aldosterone effective antihypertensives, in animal models and in pasystem (RAAS) can prevent LVH, or cause its regression tients. In SHR and other animal models of hypertension in animal models. Accordingly, a-and b-adrenoceptor they counteract the development of LVH [29, 30] . blockers, centrally acting antihypertensives that cause
The experiments with the centrally acting drugs strongly peripheral sympathoinhibition (a-methyl-DOPA, moxsuggest that sympathoinhibition is an important mechanism onidine, rilmenidine), ACE-inhibitors, calcium antagonists, in the prevention and regression of LVH, although it has and aldosterone antagonists have been shown to counteract never been explained why clonidine is ineffective in this LVH in animal models. The effect of thiazide diuretics is respect. less convincing and subject to debate, probably as a result
In this context it seems of interest to mention older of the activation of the RAAS provoked by these agents. experiments in rats with LVH caused by iron deficiency Classic potent vasodilators such as hydralazine may exanaemia. This type of LVH could be suppressed by acerbate LVH and they certainly do not prevent it, probareserpine [31] , which is known to depress sympathetic bly because of the activation of the sympathetic nervous activity both via central nervous and peripheral mechasystem and the RAAS, provoked by such compounds.
nisms. It is difficult to compare the data in experimental animals with those obtained in human patients, for a 4.2. b-Adrenoceptor antagonists (b-blockers) variety of reasons:
Several b-blockers have been shown to counteract the 1. in human studies the blood pressure differences bedevelopment of LVH in animal models of hypertension, tween treatment and control conditions are much less and this activity of the b-blockers is beyond any doubt a than in animal models, where the degree of hypertenclass effect. As an example we mention here the effects of sion is clearly more severe than found in human the b -selective agent metoprolol. Several authors have 1 hypertensives; demonstrated that prolonged therapy of SHR with an 2. most of the animal data concern the prevention of LVH antihypertensive dose of metoprolol will suppress the development, rather than the regression of established development of LVH. In SHR metoprolol was shown to LVH which is usually studied clinically; decrease wall thickness in response to the decreased pressure load (antihypertensive action), whereas it did not receptors or components of the sympathetic nervous change the LV internal radius. In SHR metoprolol treatsystem and the renin-angio-tensin-aldosterone system ment appeared to reduce the end-diastolic volume [32] .
(RAAS). Although potent vasodilators they are no more In a dog model, hypertension and LVH were induced by used in the treatment of hypertension, since they cause unilateral nephrectomy and the clipping of the contralateral reflex stimulation of the sympathetic system and probably renal artery. The animals were subsequently subjected to also of the RAAS. Accordingly, they provoke reflex coronary occlusion in order to generate myocardial infarctachycardia, a rise in plasma noradrenaline and the retion. The hypertensive animals with LVH and a myocardial tention of sodium and water. infarction showed a very high mortality [33] .
Hydralazine and minoxidil have been studied in animal Metoprolol treatment significantly reduced elevated models of hypertension, associated with LVH, in particular blood pressure, LVH and the high mortality, whereas in the SHR. It has been described repeatedly [2, 36] that infarct size was also diminished. The authors presumed hydralazine in an antihypertensive dose does not prevent or that the suppression of the aforementioned noxious pheattenuate LVH. Similar findings were obtained in transnomena by b-receptor blockade is not only explained by genic (m REN 2) 27 rats with overexpression of the mouse d the antihypertensive action but also by electro-physiologirenin 2 gene. These animals have severe hypertension and cal effects of the drug [33] .
cardiac hypertrophy [37] . The beneficial influence of b-blockers on LVH and its Conversely, in several series of experiments it was sequelae also substantiates the important role of the observed that hydralazine exacerbates LVH, as reflected by sympathetic nervous system and its transmitters in the an increased heart weight and media thickness [38] . genesis of LVH. Several authors have demonstrated the Similar observations have been made with minoxidil [39] . development of LVH as a result of the stimulation of
The lack of beneficial effect on LVH or the possibility cardiac b-adrenoceptors [14, 15] . Alterations in the cardiac that it is worsened in spite of the antihypertensive action of b-adrenoceptor-mediated signalling pathway associated such drugs may be explained by the aforementioned reflex with LVH and hypertensive heart disease have been activation of the sympathetic and renin-angiotensin-aldosrecently reviewed in detail [34] .
terone systems. In hypertrophied hearts the inotropic response to badrenoceptor agonists is known to be blunted, probably as a result of lesions of the b-adrenoceptor system, both at the 4.5. Diuretics receptor level and within the signal transduction pathway.
Although established as effective antihypertensive agents since several decades, the influence of diuretic 4.3. a-Adrenoceptor antagonists (a-blockers) agents on LVH has not been studied intensively, and hardly any comparative studies with other antihypertensives have Several a-adrenoceptor antagonists (a-blockers) have been performed. The general impression has been obtained been shown to attenuate the development of LVH, associthat diuretics are but moderately or may be not effective ated with reduction of blood pressure in animal experiwith respect to the prevention and regression of LVH. ments. In this connection we mention the example of the As an example we mention a study in SHR where both a a -adrenoceptor antagonist bunazosin, which was studied 1 thiazide diuretic (trichlormethiazide) and the loop diuretic in Dahl salt-sensitive rats [35] .
furosemide have been compared [40] . When given in rather Bunazosin was administered in a sub-antihypertensive high doses a moderate reduction of LVH (and blood dose, which did not influence the elevated blood pressure pressure) were achieved after 5 weeks of treatment. Both of these animals. However, LVH as characterized by the types of diuretics showed the same moderate efficacy on LV/ body weight ratio and the LV tissue DNA content blood pressure and the prevention of LVH. The authors proved significantly lowered by the bunazosin treatment also investigated cardiac myosin isoforms and LVH-related [35] . From these experiments the authors concluded that a gene expressions. Furosemide but not the thiazide diuretic sub-antihypertensive dose of bunazosin can inhibit the significantly increased the proportion of cardiac V3 myosin development of LVH without suppression of the pressure of the SHR by enhancing the gene expression of the load, suggesting an important role of a -adrenoceptors in 1 b-myosin heavy chain [40] . the pathogenesis of LVH subsequent to the development of Conversely, trichlormethiazide but not furosemide suphypertension.
pressed the increased cardiac gene expression of skeletal a-actin. Accordingly, the effects on the gene expression of 4.4. Direct acting vasodilators: hydralazine and cardiac contractile proteins and collagen are significantly minoxidil different among the two types of diuretics. The authors suggest that the two types of diuretics may have additional Hydralazine and minoxidil are directly acting vasodilatcardiac actions independent of their diuretic, antihyperors, which develop their vasodilator effect without blunting tensive and anti-LVH effects [40] .
Calcium antagonists
proliferative activity of the ACE-inhibitors is a class effect of these agents. Again we mention a few examples. Calcium antagonists (CA) are a rather heterogeneous Accordingly, in SHR enalapril reduced elevated blood group of anti-hypertensive and anti-anginal drugs.
pressure and LV mass in association with a decreased total Nifedipine and other dihydro-pyridines are predominantly peripheral resistance, as well as a decreased coronary potent vasodilators, without a direct effect on the cardiac vascular resistance [45] . nodal tissues in therapeutic dosages. The rapidly and short
In another series of experiments in SHR enalapril acting drugs of this type, in particular the non-retarded induced regression of cardiac hypertrophy and also nornifedipine preparation provoke sympathetic activation and malized the deranged pH regulator mechanisms associated reflex tachycardia. Conversely, the more recently introwith LVH [46] . Similarly, cilazapril treatment prevented duced dihydropyridines with a slow and long action the development of LVH and the decrease of coronary (amlodipine, lacidipine, lercanidipine) do not alter heart vascular reserve in the left and right ventricles of SHR rate. Verapamil and diltiazem are also vasodilators, but they [47] . Lisinopril was shown to reduce elevated blood reduce A-V conduction and heart rate as a result of their pressure and LVH in SHR, whereas myocardial fibrosis depressant effect on the nodal tissues. In spite of these was reversed, as a result of enhanced collagen degradation discrepancies all three different categories of CA have by activation of tissue matrix metalloproteinase 1 [48] . been shown to prevent the development of LVH in various Diastolic stiffness in advanced hypertensive heart disease animal models of hypertension. We only mention a few in SHR was improved. Systolic dysfunction of the left examples here.
ventricle could be prevented. In SHR verapamil treatment for 45 weeks significantly
The LVH in transplanted hearts of SHR was counreduced blood pressure, heart rate and the ratio of ventricuteracted by perindopril, and the authors suggested that this lar weight to body weight, as well as the collagen content effect depends on bradykinin [49] . of the heart [41] .
In rats subjected to aortic banding quinapril was shown Similarly, nifedipine treatment of SHR for 20 weeks to prevent elevated blood pressure, LVH, and to reduce caused a significant reduction of the LV muscle mass / body serum and cardiac ACE activities. Lower doses of quinapweight ratio and of the quotient of LV muscle mass and ril neither reduced blood pressure nor LVH, although they LV-end diastolic volume [42] . Accordingly, antihypertenreduced the cardiac ACE activity. It was concluded that sive treatment with nifedipine can cause an already existelevated blood pressure (pressure overload) is a more ing LVH in SHR to regress, in spite of the sympathetic important determinant than ACE activity in the genesis and activation associated with nifedipine administration. maintenance of LVH [50] . Numerous other studies, not to be mentioned here, have Similar findings were obtained in SHR with trandolapril shown prevention or regression of LVH in SHR.
[51]. In non-hypertensive models of remodelling of the heart In a dog model, where LVH was induced by rapid the suppressant effect of CA could be shown as well. For pacing, fosinopril was shown to improve LV and myocyte instance in dogs, electrical remodelling of the atrium geometry and function [16] . In cardiomyopathic hamsters during rapid atrial pacing was counteracted by verapamil enalapril was shown to prevent progressive remodelling [16] .
and to reduce cardiac dysfunction [43] . Furthermore, amlodipine, one of the newer dihydro-
In conclusion, the prevention and regression of LVH by pyridine-CA prevented progressive remodelling and a various ACE-inhibitors has been demonstrated convincingreduction of cardiac dysfunction in cardiomyopathic hamly in several animal models. sters [43] .
In conclusion, several types of CA in various models of 4.8. Angiotensin (AT )-receptor antagonists 1 cardiac hypertrophy appear to display antihypertrophic activity. In most models the reduction of high blood AT -blockers have been introduced as effective anti-1 pressure is without any doubt a major factor. Explanations hypertensive agents, which appear to be very well tolerat the cellular level are difficult to offer, since the ated. They may also be of value in the treatment of alterations in calcium handling in LVH and other types of congestive heart failure. Data concerning their influence on remodelling are not consistent and subject to debate the progression and regression of LVH are beginning to [13, 19, 44] .
emerge.
Initially there existed some doubt whether the AT - 
ACE-inhibitors
antagonists would be indeed effective as antihypertrophic agents, but more recent data may indicate that they display The ACE-inhibitors have been subjected to extensive anti-LVH activity similar to that of the ACE-inhibitors. studies with respect to their antiproliferative activity. Since
Again we briefly mention a few relevant examples. the differences between the several ACE-inhibitors now In a dog model where LVH was induced by rapid available are very modest, it seems likely that the anticardiac pacing the AT -blocker irbesartan proved less effective than the ACE-inhibitor fosinopril [52] . Moreover, tension (DBP 90-99 mm). Additional treatment with long term AT -receptor blockade in rats with aortic antihypertensives in these patients did not offer further 1 stenosis did not regress LVH [53] . However, in a detailed regression of LVH [57] . study in SHR losartan proved as effective as enalapril in A variety of antihypertensive drugs has been shown to counteracting LVH, provoked by hypertension [54] , alcause regression of LVH in treated hypertensives. though the experimental AT -blocker L-158,809 did not As described for the animal models we will mention a 1 diminish the severity of cardiomyopathy in Syrian carfew relevant examples and also discuss a meta analysis diomyopathic hamsters [55] .
concerning the effect of drug treatment. More data will be required to obtain a convincing opinion concerning the possible role of AT -blockers in 5.1. b-Blockers selective blockers bisoprolol and atenolol were shown to Endothelin (in particular ET-1) is regarded as an cause regression of LVH in hypertensive patients [58, 59] . autocrine / paracrine factor in the development of cardiac Bisoprolol was found to be similarly effective as the hypertrophy both in vivo and in vitro. For this reason ACE-inhibitor enalapril. Similar findings were obtained endothelin receptor antagonists, which are now becoming with metoprolol [60] . It is very likely that this is a class available are subjected to investigation as potential antieffect of the b-blockers, involving b -adrenoceptors. 1 proliferative agents. New data are emerging, and we mention a single example.
Diuretics The ET / ET receptor antagonist bosentan partially
A B
prevented LV dilatation and improved haemodynamics in No regression or little regression was found with rats with an MI, provoked by coronary ligation. This diuretic mono-therapy [61] , although these agents cause an finding confirms that endothelin may play a role in LV acceptable reduction of elevated blood pressure. remodelling after MI [56] .
Further investigations concerning the possible role of ET 5.3. Centrally acting antihypertensives antagonists as LVH agents are on the way. a-Methyl-DOPA and also clonidine were shown to cause regression of LVH in hypertensive patients [60].
Clinical data concerning the influence of drugs on
Moxonidine has also been shown to cause regression of LVH LVH in hypertensives [62] . The data concerning a-methyl-DOPA are on line with those described by Pegram et al. in The unfavourable effect of LVH on prognosis strongly the original publication [2] . However, Pegram et al. found suggests that regression of LVH by means of drug treatno regression of LVH by the treatment with clonidine. ment and other measures is mandatory.
Numerous investigations have shown that LVH in 5.4. Calcium antagonists hypertensives can be prevented or brought to regression by means of drug treatment and / or appropriate changes in life Nitrendipine, a dihydropyridine calcium antagonist, was style, and some of those data will be discussed in the shown to cause regression of LVH in patients with present survey.
hypertension and type II-diabetes (NIDDM) [63, 64] . ComHowever, conclusive evidence that LVH prevention or parable findings were obtained with several other dihydroregression by means of treatment indeed improves progpyridines, such as nifedipine-GITS [65] , felodipine [66] , nosis with respect to the risks of hypertensive disease has and isradipine [67] . Verapamil also caused LVH regression, so far not been published, although trials addressing this whereas in a comparative study with several other drugs question are on the way. diltiazem did not. Antihypertensive treatment as such usually leads to prevention or regression of LVH. However, the improved prognosis of treated hypertensives is primarily related to 5.5. Reserpine plus a thiazide diuretic the reduction of blood pressure as such. In the individual patient in clinical practice there is no practical and reliable
The rather old antihypertensive drug reserpine reduces method available which allows proper judgement on the blood pressure via both peripheral and central mechanisms. influence of treatment on LVH.
When combined with clopamide, a thiazide diuretic, 24 The TOMHS-Study has shown that appropriate life style weeks of treatment of hypertensives led to a reduction of changes as usual in antihypertensive treatment causes LVH and an improvement of haemodynamic parameters significant regression of LVH in patients with mild hyper-
[68].
ACE-inhibitors
follows: ACE-inhibitors, 213%; Ca-antagonists,29%; bblockers; 26% diuretics; 27%. Numerous investigations have demonstrated the beneficial effect on LVH in hypertensives. As examples we mention captopril [69] , fosinopril [70] , lisinopril [71, 72] 7. Conclusion and delapril [73] . This appears to be a class effect of the ACE-inhibitors. Furthermore, the inhibitory effect of ACE-LVH associated with hypertensive disease is widely inhibitors on remodelling of the heart in post-MI patients is recognized as an important risk factor. The desirability to also well established and probably an important mechaprevent and induce regression of LVH by drug treatment is nism in the secondary prevention in such patients. also widely understood, although the ultimate evidence that such treatment improves prognosis remains to be 5.7. Angiotensin II-receptor antagonists (AT -blockers) provided. 1 Since the early work in the 1970s, referred to in the Several AT -blockers have been shown to cause regresIntroduction of the present survey and emphasized in the 1 sion of LVH in hypertensive patients. As examples we original publication by Pegram et al. [2] , animal models mention losartan [74] , and candesartan [75] . However, have been studied on a large scale and an impressive series there has been one report on losartan causing an increase of data has been obtained. More recently modern ECHOin left ventricular mass, in spite of a clear antihypertensive techniques have allowed the investigation of LVH and the effect [76] .
influence of drugs thereupon in human patients. The impression is obtained that in animal models the vast majority of antihypertensive drugs will cause some 6. Comparative efficacy of various antihypertensive degree of LVH-prevention or suppression (depending on drugs the model used), where reduction of elevated blood pressure is a very important, but not the only factor. Several small comparative studies have been performed It goes without saying that initial blood pressure values, in order to find out which type of antihypertensive drug the duration and intensity of treatment, as well as the would be most effective in reducing LVH.
degree of LVH are important determinants of LVH regresBecause of discrepancies in methodology and low power sion or prevention. of the studies it is difficult to decide which type of the However, it has been recognized more and more that drugs would be the most effective in reducing LVH. In growth factors such as angiotensin II, catecholamines, and spite of this limitation the following comparison of the possibly insulin and human growth hormone are important activities has been proposed [77] :
factors in the development of LVH, which are influenced in ACE-inhibitors and calcium antagonists are most effeca differential manner by the various categories of antitive, whereas AT -blockers probably display comparable hypertensive drugs. There is no doubt that angiotensin II is 1 activity, although the number of investigations on these a very important factor, as demonstrated by the convincing newer drugs is limited so far. b-Blockers and even more antiproliferative effect of the ACE-inhibitors and the AT -1 so diuretics appear to be less effective than the abovereceptor antagonists. With respect to the AT -receptor 1 mentioned newer classes of antihypertensives. antagonists it may be speculated that the high concenIn a large study by the Veterans Affairs Cooperative trations of circulating angiotensin II associated with this Study Group on Antihypertensive Agents 6 different types treatment may contribute to the regression of LVH via the of antihypertensives were compared as monotherapy in stimulation of the AT -receptor [80] . Conversely, the weak 2 1105 hypertensive men [78] . After achieving the goal or absent effect of diuretics on LVH might be attributed to diastolic blood pressure of 90 mm Hg during drug titration the activation of the RAAS which is provoked by these the patients entered a 1-year maintenance period. After this agents. The sympathetic system is probably also important, period LV mass and haemodynamic parameters were as demonstrated by the anti-LVH activity of centrally measured. The most effective reduction of LVH was acting anti-hypertensives such as a-methyl-DOPA [60] and obtained by captopril, atenolol and hydrochlorothiazide.
moxonidine [62] . It is still difficult to understand why However, efficacious antihypertensive treatment with dilclonidine was ineffective in some animal models (see the tiazem, clonidine or prazosin did not cause significant original publication by Pegram et al. [2] ). The moderate reductions of LVH. The authors concluded that antiefficacy of the b-blockers with respect to LVH regression / hypertensive drugs have disparate effects on LV mass prevention would indicate that the interaction of cardiac independent of the magnitude of blood pressure reduction.
b-adrenoceptors with circulating catecholamines is proba-A recent meta-analysis of randomized double-blind bly not a very important factor in the development or trials [79] has shown that after a mean duration of regression of LVH. treatment of 25 weeks, with approximately equi-effective In summary, since the publication of the paper by antihypertensive doses of the drugs, LV mass decreased as Pegram et al. in 1982 [2] , LVH has been the subject of responses after monocrotaline-induced hypertrophy in rats. J Carintensive research, which has greatly deepened our insight pressed inotropic response to beta-adrenoceptor agonists in the presence of advanced cardiac hypertrophy in hearts from rats with induced aortic stenosis and from spontaneously hypertensive rats. J Hypertens 1992;10:1361-1368.
